Zimmer Biomet’s (ZBH) “Hold” Rating Reiterated at BTIG Research

BTIG Research restated their hold rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report released on Monday morning, AnalystRatings.com reports.

Several other research analysts also recently commented on the company. Cowen set a $140.00 price objective on Zimmer Biomet and gave the stock a hold rating in a report on Friday, July 26th. Jefferies Financial Group boosted their price target on Zimmer Biomet from $150.00 to $167.00 and gave the company a buy rating in a report on Monday, July 29th. They noted that the move was a valuation call. Zacks Investment Research upgraded Zimmer Biomet from a hold rating to a buy rating and set a $149.00 price target on the stock in a report on Saturday, August 31st. Sanford C. Bernstein upgraded Zimmer Biomet from an underperform rating to a market perform rating and set a $121.71 price target on the stock in a report on Tuesday, June 11th. Finally, Credit Suisse Group boosted their price target on Zimmer Biomet from $101.00 to $120.00 and gave the company an underperform rating in a report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seventeen have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $143.99.

ZBH opened at $139.41 on Monday. The company has a market cap of $28.50 billion, a P/E ratio of 18.25, a P/E/G ratio of 2.48 and a beta of 1.15. The business’s 50-day moving average price is $137.55 and its 200-day moving average price is $125.78. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. Zimmer Biomet has a 12 month low of $96.99 and a 12 month high of $143.57.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The firm had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The company’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.92 earnings per share. Equities research analysts forecast that Zimmer Biomet will post 7.82 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Friday, September 27th. This represents a $0.96 annualized dividend and a yield of 0.69%. Zimmer Biomet’s payout ratio is 12.57%.

In other Zimmer Biomet news, VP Chad F. Phipps sold 32,800 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $140.00, for a total transaction of $4,592,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Didier Deltort sold 360 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the sale, the insider now directly owns 1,194 shares in the company, valued at $166,264.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,391 shares of company stock worth $5,642,274. Insiders own 0.72% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ZBH. Geode Capital Management LLC boosted its position in Zimmer Biomet by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock valued at $273,516,000 after acquiring an additional 205,532 shares in the last quarter. United Bank boosted its position in shares of Zimmer Biomet by 9.9% in the 1st quarter. United Bank now owns 11,003 shares of the medical equipment provider’s stock worth $1,405,000 after purchasing an additional 988 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Zimmer Biomet by 2.5% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 23,023 shares of the medical equipment provider’s stock worth $2,940,000 after purchasing an additional 567 shares in the last quarter. Raymond James & Associates boosted its position in shares of Zimmer Biomet by 5.1% in the 1st quarter. Raymond James & Associates now owns 114,347 shares of the medical equipment provider’s stock worth $14,602,000 after purchasing an additional 5,535 shares in the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD boosted its position in shares of Zimmer Biomet by 6.1% in the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 14,083 shares of the medical equipment provider’s stock worth $1,798,000 after purchasing an additional 806 shares in the last quarter. 87.83% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: What is the Fibonacci sequence?

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.